In Business 32 Years - Since 1980
THE CURRENT TIME at LC Labs is:
|
|
||||||
In Business 32 Years - Since 1980 |
THE CURRENT TIME at LC Labs is: |
|||||
[Telatinib] [17-(Allylamino)-17-demethoxygeldanamycin] [17-(Allylamino)geldanamycin] [Tanespimycin]
|
 |
 |
|
Size |
US $ |
€ |
£ |
¥ |
|
||
|
25 mg |
42 |
32 |
27 |
3200 |
| ||
|
100 mg |
87 |
66 |
55 |
6700 |
| ||
|
200 mg |
154 |
117 |
97 |
11800 |
| ||
|
250 mg |
183 |
139 |
116 |
14000 |
| ||
|
500 mg |
248 |
188 |
157 |
19000 |
| ||
|
1 g |
425 |
323 |
269 |
32600 |
| ||
|
2 g |
728 |
553 |
460 |
55800 |
| ||
|
5 g |
1185 |
900 |
749 |
90800 |
| ||
|
10 g |
1890 |
1436 |
1195 |
144900 |
| ||
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
| Compare Prices and Purity — LC Labs vs. Other Suppliers |
|---|
M.W. 585.69
C31H43N3O8
[75747-14-7]
Warning: Toxic.
Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 150 mg/mL; soluble in ethanol at 5 mg/mL; very poorly soluble in water; maximum solubility in plain water is estimated to be about 20-50 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A
Find and View a Certificate of Analysis for this product
View the MSDS for this product
Semi-synthetic derivative of geldanamycin, Cat. No. G-4500, demonstrating greater stability and lower in vivo toxicity than its parent compound. 17-AAG binds specifically to heat shock protein Hsp90 in a manner similar to geldanamycin, but the binding is weaker. Schulte, T.W. and Neckers, L.M. "The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin." Cancer Chemother. Pharmacol. 42: 273-279 (1998).
Inhibits Akt activation and HER2 expression in tumor cells. Basso, A.D., et al. "Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2." Oncogene 21: 1159-1166 (2002).
Exhibits 100-fold higher binding affinity for tumor-cell-derived hsp90 over that derived from normal cells. Kamal, A., et al. "A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors." Nature 425: 407-10 (2003).
Sensitizes tumor cells to growth arrest and apoptosis induced by paclitaxel, Cat. No. P-9600. Nguyen, D.M., et al. "Sequence-dependent enhancement of paclitaxel toxicity in non-small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin." J. Thorac. Cardiovasc. Surg. 118: 908-915 (1999) and Solit, D.B., et al. "Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol." Cancer Res. 63: 2139-2144 (2003).
Sensitizes colon cancer cells to cisplatin-induced cell death. Vasilevskaya, I.A., et al. "Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines." Mol Pharmacol. 65: 235-243 (2004).
Inhibits angiogenesis. Kaur, G, et al. "Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator." Clin. Cancer Res. 10: 4813-4821 (2004).
Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
Our products are for laboratory research only and are sold only to qualified research institutions, not to individuals or patients nor for veterinary use.
